Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Slides:

Advertisements

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Advertisements

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

The Epidemic of the 20th Century: Coronary Heart Disease

Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema Harikrishna Makani, MD, Sripal Bangalore, MD, MHA,

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

New-onset Atrial Fibrillation Predicts Heart Failure Progression

The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence David D. Waters, MD, Sripal Bangalore, MD,

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

Salt, Tomato Soup, and the Hypocrisy of the American Heart Association

Personalized Activity Intelligence (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity Bjarne M. Nes, PhD, Christian R.

TNT: Baseline and final LDL cholesterol levels

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Sripal Bangalore, MD,

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Masaya Koshizaka, MD, PhD, Renato D. Lopes, MD, PhD, MHS, L

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review Shelley R. Salpeter, MD, Jacob S.

Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction Stein Ørn, MD, John G.F. Cleland, MD, Matti.

Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis Islam Y. Elgendy,

Matthew A. Cavender, MD, MPH, Benjamin M

Introduction The American Journal of Medicine

Matthew I. Worthley, MBBS, PhD, FRACP, Fiona M

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Trends in Stroke Rates, Risk, and Outcomes in the United States, 1988 to 2008 Margaret C. Fang, MD, MPH, Marcelo Coca Perraillon, MA, Kaushik Ghosh, PhD,

Sayed H. Naderi, BMedSci, Jonathan P. Bestwick, MSc, David S. Wald, MD

Wandering Acute Myocardial Infarction

Todd A. Lee, PharmD, PhD, Brian Bartle, MPH, Kevin B. Weiss, MD, MPH

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

The Effect of a Statewide Smoking Ordinance on Acute Myocardial Infarction Rates Paul Basel, BS, Becki Bucher Bartelson, PhD, Marie Claire Le Lait, MS,

The Epidemic of the 20th Century: Coronary Heart Disease

Carotid Sinus Massage in Patients with Suspected Acute Myocardial Infarction, Tachycardia, and Left Bundle Branch Block Teddy Weiss, MD, Yair Elitzur,

Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of comparative studies Hisato Takagi,

Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction Victoria Hamill, PhD, Ian Ford, PhD, Kim Fox, MD,

Age and Gender Differences in Quality of Care and Outcomes for Patients with ST- segment Elevation Myocardial Infarction Sripal Bangalore, MD, MHA, Gregg.

Adherence to Secondary Prevention Medications and Four-year Outcomes in Outpatients with Atherosclerosis Dharam J. Kumbhani, MD, SM, MRCP, Ph. Gabriel.

Muhammad Amer, MD, MHS, FACP, Rehan Qayyum, MD, MHS

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

Gun Ownership and Firearm-related Deaths

Syncope: Outcomes and Conditions Associated with Hospitalization

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

Clinical Outcomes with β-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials Sripal Bangalore, MD, MHA, Harikrishna Makani, MD,

Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis G. Caleb Alexander, MD, MS, Geetha Iyer, MBBS, Eleanor.

Interaction of Physical Activity and Body Mass Index on Mortality in Coronary Heart Disease: Data from the Nord-Trøndelag Health Study Trine Moholdt,

When Guidelines Cause Hypertension

Molly E. Waring, PhD, Jane S

Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An INVEST Substudy Scott J. Denardo, MD, Yan Gong, PhD, Wilmer.

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

On Statin Treatment to Prevent Sepsis in Dialysis Patients

The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation David.

Yader Sandoval, MD, Stephen W. Smith, MD, Sara A

Clinical Outcomes After Treatment of Cocaine-Induced Chest Pain with Beta-Blockers: A Systematic Review and Meta-Analysis Kevin Bryan Lo, MD, Hafeez.

MATCH Results: Implications for the Internist

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Nilay S. Shah, MD, MPH, David Leonard, PhD, Carrie E

Age Differences in Treatment and Control of Hypertension in US Physician Offices, : A Serial Cross-sectional Study Anna Gu, MD, PhD, Yu Yue,

Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema Harikrishna Makani, MD, Sripal Bangalore, MD, MHA,

Role of Niacin in Current Clinical Practice: A Systematic Review

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

When Guidelines Need Guidance…

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Temporal trends in the incidence of coronary disease

Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex Naji Kholaif,

Higher Cardiovascular Disease Prevalence and Mortality among Younger Blacks Compared to Whites Stacey Jolly, MD, MS, Eric Vittinghoff, PhD, Arpita Chattopadhyay,

FIELD: Primary outcome

Toward a More Responsible News Media

Daniel E. Weiner, MD, MS, Hocine Tighiouart, MS, John L

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States Ahmet Ergin, MD, PhD, MPH, Paul.

Sex Differences in the Management and 5-Year Outcome of Young Patients (

Presentation transcript:

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD, Rachel Laskey, PhD, David A. DeMicco, PharmD, Prakash Deedwania, MD, John B. Kostis, MD, Franz H. Messerli, MD The American Journal of Medicine Volume 127, Issue 1, Pages 71-81.e1 (January 2014) DOI: 10.1016/j.amjmed.2013.07.038 Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 1 Apparent treatment-resistant hypertension and the risk of primary and secondary outcomes. aTRH = apparent treatment-resistant hypertension; CI = confidence interval; HR = hazard ratio. The American Journal of Medicine 2014 127, 71-81.e1DOI: (10.1016/j.amjmed.2013.07.038) Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 2 (A) Cumulative incidence of primary outcome (death from coronary heart disease, nonfatal nonprocedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke) between patients with and without apparent treatment-resistant hypertension. (B) Cumulative incidence of coronary heart disease deaths between patients with and without apparent treatment-resistant hypertension. (C) Cumulative incidence of nonfatal myocardial infarction between patients with and without apparent treatment-resistant hypertension. aTRH = apparent treatment-resistant hypertension; CHD = coronary heart disease; HR = hazard ratio. The American Journal of Medicine 2014 127, 71-81.e1DOI: (10.1016/j.amjmed.2013.07.038) Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 3 (A) Cumulative incidence of first major coronary events (death from coronary heart disease, nonfatal nonprocedure-related myocardial infarction, or resuscitation after cardiac arrest) between patients with and without apparent treatment-resistant hypertension. (B) Cumulative incidence of heart failure between patients with and without apparent treatment-resistant hypertension. (C) Cumulative incidence of all-cause mortality between patients with and without apparent treatment-resistant hypertension. (D) Cumulative incidence of any coronary events (revascularization procedure, procedure-related myocardial infarction, or documented angina) between patients with and without apparent treatment-resistant hypertension. (E) Cumulative incidence of any cardiovascular event between patients with and without apparent treatment-resistant hypertension. (F) Cumulative incidence of angina pectoris between patients with and without apparent treatment-resistant hypertension. (G) Cumulative incidence of coronary revascularization between patients with and without apparent treatment-resistant hypertension. aTRH = apparent treatment-resistant hypertension; HR = hazard ratio. The American Journal of Medicine 2014 127, 71-81.e1DOI: (10.1016/j.amjmed.2013.07.038) Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 3 (A) Cumulative incidence of first major coronary events (death from coronary heart disease, nonfatal nonprocedure-related myocardial infarction, or resuscitation after cardiac arrest) between patients with and without apparent treatment-resistant hypertension. (B) Cumulative incidence of heart failure between patients with and without apparent treatment-resistant hypertension. (C) Cumulative incidence of all-cause mortality between patients with and without apparent treatment-resistant hypertension. (D) Cumulative incidence of any coronary events (revascularization procedure, procedure-related myocardial infarction, or documented angina) between patients with and without apparent treatment-resistant hypertension. (E) Cumulative incidence of any cardiovascular event between patients with and without apparent treatment-resistant hypertension. (F) Cumulative incidence of angina pectoris between patients with and without apparent treatment-resistant hypertension. (G) Cumulative incidence of coronary revascularization between patients with and without apparent treatment-resistant hypertension. aTRH = apparent treatment-resistant hypertension; HR = hazard ratio. The American Journal of Medicine 2014 127, 71-81.e1DOI: (10.1016/j.amjmed.2013.07.038) Copyright © 2014 Elsevier Inc. Terms and Conditions